<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33605846</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2164-554X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human vaccines &amp; immunotherapeutics</Title>
          <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease.</ArticleTitle>
        <Pagination>
          <StartPage>1872341</StartPage>
          <MedlinePgn>1872341</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">1872341</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2021.1872341</ELocationID>
        <Abstract>
          <AbstractText>The worldwide implementation of pneumococcal conjugate vaccines (PCVs) in children has reduced the overall pneumococcal disease burden. Two PCVs are widely available for infant vaccination: the pneumococcal non-typeable <i>Haemophilus influenzae</i> protein D conjugate vaccine (PHiD-CV) and the 13-valent PCV (PCV13). While these PCVs differ in serotype composition (PCV13 includes polysaccharides of serotypes 3, 6A and 19A; PHiD-CV does not), their impact on the overall pneumococcal disease burden in children is comparable. This commentary summarizes the evidence of comparability between PHiD-CV and PCV13 and explores why differences in serotype composition may not necessarily translate into a differential clinical impact. Both vaccines confer similarly high protection against disease caused by vaccine serotypes and lead to a partial replacement by non-vaccine serotypes. PHiD-CV does not protect against serotype 3 disease (not included in the vaccine) and PCV13's effect on this serotype has been inconsistent. PHiD-CV provides some cross-protection against disease caused by vaccine-related serotype 19A but neither vaccine has fully controlled 19A disease. While protection against 19A is higher for PCV13 than PHiD-CV, replacement by non-PCV13 serotypes in settings with a PCV13 program appears to compensate for this difference. This results in a similar residual overall disease burden with both vaccines.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Izurieta</LastName>
            <ForeName>Patricia</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0001-5703-3151</Identifier>
            <AffiliationInfo>
              <Affiliation>GSK, Wavre, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nieto Guevara</LastName>
            <ForeName>Javier</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-3073-2830</Identifier>
            <AffiliationInfo>
              <Affiliation>GSK, Panama City, Panama.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hum Vaccin Immunother</MedlineTA>
        <NlmUniqueID>101572652</NlmUniqueID>
        <ISSNLinking>2164-5515</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D022242">Pneumococcal Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018074">Vaccines, Conjugate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011008" MajorTopicYN="Y">Pneumococcal Infections</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022242" MajorTopicYN="N">Pneumococcal Vaccines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013296" MajorTopicYN="N">Streptococcus pneumoniae</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018074" MajorTopicYN="N">Vaccines, Conjugate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherAbstract Type="plain-language-summary" Language="eng">
        <AbstractText>PLAIN LANGUAGE SUMMARY<b>What is the context?</b>The pneumococcus bacterium can cause infections of the meninges, blood, lung, middle ear and sinuses.Two vaccins, <i>Synflorix</i> (GSK) and <i>Prevnar</i> 13 (Pfizer Inc.), are widely used to protect young children against these infections.The vaccines’ compositions differ: <i>Synflorix</i> includes antigens from 10 pneumococcus strains (or “serotypes”) and <i>Prevnar</i> 13 from 13 serotypes.However, both have a similar effect on the total pneumococcal disease burden in children.<b>What does this commentary highlight?</b>This commentary summarizes the evidence beihnd the two vaccines’ comparable impact on pneumococcal disase.It also looks at why the vaccines have a similar effect on the total pneumococcal disease burden despite their different compositions.<b>What is the impact on current thinking?</b>Given that <i>Synflorix</i> and <i>Prevnar</i> 13 have a comparable impact on pneumococcal disease, a country’s choice between the two vaccines will depend on vaccine supply, cost, logistical factors (e.g., transport, storage, training requirements of health workers) and the local pneumococcal epidemiology.</AbstractText>
      </OtherAbstract>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">PCV10</Keyword>
        <Keyword MajorTopicYN="Y">PCV13</Keyword>
        <Keyword MajorTopicYN="Y">PHiD-CV</Keyword>
        <Keyword MajorTopicYN="Y">Pneumococcal conjugate vaccine</Keyword>
        <Keyword MajorTopicYN="Y">children</Keyword>
        <Keyword MajorTopicYN="Y">invasive pneumococcal disease</Keyword>
        <Keyword MajorTopicYN="Y">otitis media</Keyword>
        <Keyword MajorTopicYN="Y">pneumonia</Keyword>
        <Keyword MajorTopicYN="Y">replacement</Keyword>
        <Keyword MajorTopicYN="Y">serotypes</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>12</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33605846</ArticleId>
        <ArticleId IdType="pmc">PMC8920200</ArticleId>
        <ArticleId IdType="doi">10.1080/21645515.2021.1872341</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T.. 
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–8. doi:10.1016/s0140-6736(09)61204-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(09)61204-6</ArticleId>
            <ArticleId IdType="pubmed">19748398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Luksic I, Nair H, McAllister DA, Campbell H, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018;6(7):e744–e757. doi:10.1016/s2214-109x(18)30247-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s2214-109x(18)30247-x</ArticleId>
            <ArticleId IdType="pmc">PMC6005122</ArticleId>
            <ArticleId IdType="pubmed">29903376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization . Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – February 2019. Wkly Epidemiol Rec. 2019;94(8):85–104.</Citation>
        </Reference>
        <Reference>
          <Citation>Ganaie F, Saad JS, McGee L, van Tonder AJ, Bentley SD, Lo SW, Gladstone RA, Turner P, Keenan JD, Breiman RF, et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus. mBio.
2020;11(3):e00937–00920. doi:10.1128/mBio.00937-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mBio.00937-20</ArticleId>
            <ArticleId IdType="pmc">PMC7240158</ArticleId>
            <ArticleId IdType="pubmed">32430472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cherian T. WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26-27 October 2006, Geneva. Vaccine. 2007;25(36):6557–64. doi:10.1016/j.vaccine.2007.06.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2007.06.044</ArticleId>
            <ArticleId IdType="pubmed">17681648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30(1):122–40. doi:10.1086/313609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/313609</ArticleId>
            <ArticleId IdType="pubmed">10619741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30(1):100–21. doi:10.1086/313608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/313608</ArticleId>
            <ArticleId IdType="pubmed">10619740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, Muenz LR, O’Brien KL. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7(10):e1000348. doi:10.1371/journal.pmed.1000348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pmed.1000348</ArticleId>
            <ArticleId IdType="pmc">PMC2950132</ArticleId>
            <ArticleId IdType="pubmed">20957191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen O, Knoll M, O’Brien K, Ramakrishnan M, Constenla D, Privor-Dumm L, Buss-Younkin J, Farrar J, Pilishvili T, Whitney C, et al. Pneumococcal conjugate vaccine (PCV) product assessment. 2017.  [accessed 2020 June
3]. https://www.jhsph.edu/ivac/wp-content/uploads/2018/05/pcv-product-assessment-april-25-2017.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Poolman JT, Peeters CC, van den Dobbelsteen GP. The history of pneumococcal conjugate vaccine development: dose selection. Expert Rev Vaccines. 2013;12(12):1379–94. doi:10.1586/14760584.2013.852475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14760584.2013.852475</ArticleId>
            <ArticleId IdType="pubmed">24195479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Oliveira LH, Camacho LA, Coutinho ES, Martinez-Silveira MS, Carvalho AF, Ruiz-Matus C, Toscano CM. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: a systematic review. PLoS One. 2016;11(12):e0166736. doi:10.1371/journal.pone.0166736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0166736</ArticleId>
            <ArticleId IdType="pmc">PMC5152835</ArticleId>
            <ArticleId IdType="pubmed">27941979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen O, Knoll M, O’Brien K, Ramakrishnan M, Farrar J, Pilishvili T, Whitney C, Goldblatt D, Moisi J, de Cola M, et al. Pneumococcal conjugate vaccine (PCV) review of impact evidence (PRIME): summary of findings from systematic review. 2017. 
Oct [accessed 2020 June
3]. https://www.who.int/immunization/sage/meetings/2017/october/3_FULL_PRIME_REPORT_2017Sep26.pdf?ua=1.</Citation>
        </Reference>
        <Reference>
          <Citation>Naucler P, Galanis I, Morfeldt E, Darenberg J, Ortqvist A, Henriques-Normark B. Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations. Clin Infect Dis. 2017;65(11):1780–89. doi:10.1093/cid/cix685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/cix685</ArticleId>
            <ArticleId IdType="pmc">PMC5848315</ArticleId>
            <ArticleId IdType="pubmed">29020171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33(23):2684–89. doi:10.1016/j.vaccine.2015.04.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2015.04.005</ArticleId>
            <ArticleId IdType="pubmed">25887086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gouvernement du Québec . Advice and prevention - pneumococcal conjugate vaccine. 2018.  [accessed 2020 June
3]. https://www.quebec.ca/en/health/advice-and-prevention/vaccination/pneumococcal-conjugate-vaccine/.</Citation>
        </Reference>
        <Reference>
          <Citation>Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495–502. doi:10.1016/s0140-6736(06)69637-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(06)69637-2</ArticleId>
            <ArticleId IdType="pubmed">17071283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378(9807):1962–73. doi:10.1016/s0140-6736(10)62225-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(10)62225-8</ArticleId>
            <ArticleId IdType="pmc">PMC3256741</ArticleId>
            <ArticleId IdType="pubmed">21492929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Domingues CM, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, Santos JB, de Moraes JC. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2(6):464–71. doi:10.1016/s2213-2600(14)70060-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s2213-2600(14)70060-8</ArticleId>
            <ArticleId IdType="pubmed">24726406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rinta-Kokko H, Auranen K, Toropainen M, Nuorti JP, Nohynek H, Siira L, Palmu AA. Effectiveness of 10-valent pneumococcal conjugate vaccine estimated with three parallel study designs among vaccine-eligible children in Finland. Vaccine. 2020;38(6):1559–64. doi:10.1016/j.vaccine.2019.11.049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2019.11.049</ArticleId>
            <ArticleId IdType="pubmed">31791813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verani JR, Domingues CM, de Moraes JC. Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group. Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease. Vaccine. 2015;33(46):6145–48. doi:10.1016/j.vaccine.2015.10.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2015.10.007</ArticleId>
            <ArticleId IdType="pmc">PMC6859415</ArticleId>
            <ArticleId IdType="pubmed">26469718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riaz A, Mohiuddin S, Husain S, Yousafzai MT, Sajid M, Kabir F, Rehman NU, Mirza W, Salam B, Nadeem N, et al. Effectiveness of 10-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in Pakistan. Int J Infect Dis. 2019;80:28–33. doi:10.1016/j.ijid.2018.12.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijid.2018.12.007</ArticleId>
            <ArticleId IdType="pubmed">30576865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berman-Rosa M, O’Donnell S, Barker M, Quach C. Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease. Pediatrics.
2020;145(4):e20190377. doi:10.1542/peds.2019-0377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2019-0377</ArticleId>
            <ArticleId IdType="pubmed">32156773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–46. doi:10.1016/s1473-3099(14)70822-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1473-3099(14)70822-9</ArticleId>
            <ArticleId IdType="pubmed">25042756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinberger R, van der Linden M, Imohl M, von Kries R. Vaccine effectiveness of PCV13 in a 3+1 vaccination schedule. Vaccine. 2016;34(18):2062–65. doi:10.1016/j.vaccine.2016.02.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2016.02.043</ArticleId>
            <ArticleId IdType="pubmed">26920471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen C, von Mollendorf C, de Gouveia L, Lengana S, Meiring S, Quan V, Nguweneza A, Moore DP, Reubenson G, Moshe M, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study. Lancet Glob Health. 2017;5(3):e359–e369. doi:10.1016/s2214-109x(17)30043-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s2214-109x(17)30043-8</ArticleId>
            <ArticleId IdType="pubmed">28139443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dominguez A, Ciruela P, Hernandez S, Garcia-Garcia JJ, Soldevila N, Izquierdo C, Moraga-Llop F, Diaz A, de Sevilla MF, Gonzalez-Peris S, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. PLoS One. 2017;12(8):e0183191. doi:10.1371/journal.pone.0183191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0183191</ArticleId>
            <ArticleId IdType="pmc">PMC5555701</ArticleId>
            <ArticleId IdType="pubmed">28806737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gidding HF, McCallum L, Fathima P, Moore HC, Snelling TL, Blyth CC, Jayasinghe S, Giele C, de Klerk N, Andrews RM, et al. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia. Vaccine. 2018;36(19):2650–56. doi:10.1016/j.vaccine.2018.03.058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2018.03.058</ArticleId>
            <ArticleId IdType="pubmed">29627233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-valent pneumococcal conjugate vaccines in a schedule without a booster dose: a 10-year observational study. Clin Infect Dis. 2018;67(3):367–74. doi:10.1093/cid/ciy129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciy129</ArticleId>
            <ArticleId IdType="pubmed">29471432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, Zansky SM, Rosen JB, Reingold A, Scherzinger K, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016;4(5):399–406. doi:10.1016/s2213-2600(16)00052-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s2213-2600(16)00052-7</ArticleId>
            <ArticleId IdType="pubmed">26987984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Linden M, Falkenhorst G, Perniciaro S, Fitzner C, Imohl M. Effectiveness of pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany. PLoS One. 2016;11(8):e0161257. doi:10.1371/journal.pone.0161257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0161257</ArticleId>
            <ArticleId IdType="pmc">PMC4985133</ArticleId>
            <ArticleId IdType="pubmed">27526117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guevara M, Barricarte A, Torroba L, Herranz M, Gil-Setas A, Gil F, Bernaola E, Ezpeleta C, Castilla J. Working Group for Surveillance of the Pneumococcal Invasive Disease in Navarra. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case-control study. Euro Surveill. 2016;21(14). doi:10.2807/1560-7917.Es.2016.21.14.30186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2807/1560-7917.Es.2016.21.14.30186</ArticleId>
            <ArticleId IdType="pubmed">27103428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomczyk S, Lessa FC, Sanchez J, Peña C, Fernandez J, Gloria Carvalho M, Pimenta F, Cedano D, Whitney CG, Verani JR, et al. Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic. BMC Infect Dis. 2018;18(1):152. doi:10.1186/s12879-018-3047-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12879-018-3047-3</ArticleId>
            <ArticleId IdType="pmc">PMC5880020</ArticleId>
            <ArticleId IdType="pubmed">29609548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381(9862):214–22. doi:10.1016/s0140-6736(12)61854-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(12)61854-6</ArticleId>
            <ArticleId IdType="pubmed">23158882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tregnaghi MW, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11(6):e1001657. doi:10.1371/journal.pmed.1001657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pmed.1001657</ArticleId>
            <ArticleId IdType="pmc">PMC4043495</ArticleId>
            <ArticleId IdType="pubmed">24892763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews N, Kent A, Amin-Chowdhury Z, Sheppard C, Fry N, Ramsay M, Ladhani SN. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006-2018. Vaccine. 2019;37(32):4491–98. doi:10.1016/j.vaccine.2019.06.071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2019.06.071</ArticleId>
            <ArticleId IdType="pubmed">31272872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linley E, Bell A, Gritzfeld JF, Borrow R. Should pneumococcal serotype 3 be included in serotype-specific immunoassays?
Vaccines (Basel). 2019;7(1):4. doi:10.3390/vaccines7010004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/vaccines7010004</ArticleId>
            <ArticleId IdType="pmc">PMC6466091</ArticleId>
            <ArticleId IdType="pubmed">30609868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines. 2011;10(3):307–22. doi:10.1586/erv.11.8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/erv.11.8</ArticleId>
            <ArticleId IdType="pubmed">21434799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hausdorff WP, Hanage WP. Interim results of an ecological experiment - conjugate vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother. 2016;12(2):358–74. doi:10.1080/21645515.2015.1118593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2015.1118593</ArticleId>
            <ArticleId IdType="pmc">PMC5049718</ArticleId>
            <ArticleId IdType="pubmed">26905681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Izurieta P, Bahety P, Adegbola R, Clarke C, Hoet B. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution. Expert Rev Vaccines. 2018;17(6):479–93. doi:10.1080/14760584.2018.1413354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14760584.2018.1413354</ArticleId>
            <ArticleId IdType="pubmed">29241390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12(5):e0177113. doi:10.1371/journal.pone.0177113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0177113</ArticleId>
            <ArticleId IdType="pmc">PMC5423631</ArticleId>
            <ArticleId IdType="pubmed">28486544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Andrews NJ, Miller E, Ramsay ME. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–51. doi:10.1016/s1473-3099(18)30052-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1473-3099(18)30052-5</ArticleId>
            <ArticleId IdType="pubmed">29395999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernandez S, Moraga-Llop F, Diaz A, de Sevilla MF, Ciruela P, Muñoz-Almagro C, Codina G, Campins M, Garcia-Garcia JJ, Esteva C, et al. Failures of 13-valent conjugated pneumococcal vaccine in age-appropriately vaccinated children 2-59 months of age, Spain. Emerg Infect Dis. 2020;26(6):1147–55. doi:10.3201/eid2606.190951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3201/eid2606.190951</ArticleId>
            <ArticleId IdType="pmc">PMC7258469</ArticleId>
            <ArticleId IdType="pubmed">32441620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oligbu G, Collins S, Andrews N, Sheppard CL, Fry NK, Slack MPE, Borrow R, Ladhani SN. Characteristics and serotype distribution of childhood cases of invasive pneumococcal disease following pneumococcal conjugate vaccination in England and Wales, 2006-2014. Clin Infect Dis. 2017;65(7):1191–98. doi:10.1093/cid/cix418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/cix418</ArticleId>
            <ArticleId IdType="pubmed">29309553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines. 2009;8(11):1479–500. doi:10.1586/erv.09.113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/erv.09.113</ArticleId>
            <ArticleId IdType="pubmed">19863240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, Virolainen-Julkunen A, Toropainen M, Nuorti JP. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children – a population-based study. PLoS One. 2015;10(3):e0120290. doi:10.1371/journal.pone.0120290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0120290</ArticleId>
            <ArticleId IdType="pmc">PMC4364013</ArticleId>
            <ArticleId IdType="pubmed">25781031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rinta-Kokko H, Palmu AA, Auranen K, Nuorti JP, Toropainen M, Siira L, Virtanen MJ, Nohynek H, Jokinen J. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. Vaccine. 2018;36(15):1934–40. doi:10.1016/j.vaccine.2018.03.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2018.03.001</ArticleId>
            <ArticleId IdType="pubmed">29526371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grant LR, O’Brien SE, Burbidge P, Haston M, Zancolli M, Cowell L, Johnson M, Weatherholtz RC, Reid R, Santosham M, et al. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PLoS One. 2013;8(9):e74906. doi:10.1371/journal.pone.0074906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0074906</ArticleId>
            <ArticleId IdType="pmc">PMC3781100</ArticleId>
            <ArticleId IdType="pubmed">24086394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su WJ, Lo HY, Chang CH, Chang LY, Chiu CH, Lee PI, Lu CY, Hsieh YC, Lai MS, Lin TY. Effectiveness of pneumococcal conjugate vaccines of different valences against invasive pneumococcal disease among children in Taiwan: a nationwide study. Pediatr Infect Dis J. 2016;35(4):e124–133. doi:10.1097/inf.0000000000001054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/inf.0000000000001054</ArticleId>
            <ArticleId IdType="pubmed">26974752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieto Guevara J, Izurieta P, Hoet B. Response to: pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
Expert Rev Vaccines. 2018;17(4):283–84. doi:10.1080/14760584.2018.1459247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14760584.2018.1459247</ArticleId>
            <ArticleId IdType="pubmed">29611439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kandasamy R, Voysey M, Collins S, Berbers G, Robinson H, Noel I, Hughes H, Ndimah S, Gould K, Fry N, et al. Persistent circulation of vaccine serotypes and serotype replacement after 5 years of infant immunization with 13-valent pneumococcal conjugate vaccine in the United Kingdom. J Infect Dis. 2020;221(8):1361–70. doi:10.1093/infdis/jiz178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiz178</ArticleId>
            <ArticleId IdType="pubmed">31004136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desmet S, Lagrou K, Wyndham-Thomas C, Braeye T, Verhaegen J, Maes P, Fieuws S, Peetermans WE, Blumental S. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study. Lancet Infect Dis. 2020;21:127–36. doi:10.1016/s1473-3099(20)30173-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1473-3099(20)30173-0</ArticleId>
            <ArticleId IdType="pubmed">32702303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hausdorff WP, Hoet B, Adegbola RA. Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough. Expert Rev Vaccines. 2015;14(3):413–28. doi:10.1586/14760584.2015.965160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14760584.2015.965160</ArticleId>
            <ArticleId IdType="pubmed">25266168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu Seir R, Azmi K, Hamdan A, Namouz H, Jaar F, Jaber H, Rubin C, Doron D, Rahav G, Abdeen Z, et al. Comparison of early effects of pneumococcal conjugate vaccines: PCV7, PCV10 and PCV13 on Streptococcus pneumoniae nasopharyngeal carriage in a population based study; The Palestinian-Israeli Collaborative Research (PICR). PLoS One. 2018;13(11):e0206927. doi:10.1371/journal.pone.0206927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0206927</ArticleId>
            <ArticleId IdType="pmc">PMC6231627</ArticleId>
            <ArticleId IdType="pubmed">30418989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, Moisi JC, Adetifa IM, Karani A, Akech DO, et al. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet. 2019;393(10186):2146–54. doi:10.1016/s0140-6736(18)33005-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(18)33005-8</ArticleId>
            <ArticleId IdType="pmc">PMC6548991</ArticleId>
            <ArticleId IdType="pubmed">31000194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Southern J, Andrews N, Sandu P, Sheppard CL, Waight PA, Fry NK, Van Hoek AJ, Miller E. Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England. PLoS One. 2018;13(5):e0195799. doi:10.1371/journal.pone.0195799.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0195799</ArticleId>
            <ArticleId IdType="pmc">PMC5969732</ArticleId>
            <ArticleId IdType="pubmed">29799839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Usuf E, Bottomley C, Bojang E, Cox I, Bojang A, Gladstone R, Kampmann B, Hill PC, Roca A. Persistence of nasopharyngeal pneumococcal vaccine serotypes and increase of nonvaccine serotypes among vaccinated infants and their mothers 5 years after introduction of pneumococcal conjugate vaccine 13 in The Gambia. Clin Infect Dis. 2019;68(9):1512–21. doi:10.1093/cid/ciy726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciy726</ArticleId>
            <ArticleId IdType="pmc">PMC6481996</ArticleId>
            <ArticleId IdType="pubmed">30165376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vissers M, Wijmenga-Monsuur AJ, Knol MJ, Badoux P, van Houten MA, van der Ende A, Sanders EAM, Rots NY. Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands. PLoS One. 2018;13(3):e0194823. doi:10.1371/journal.pone.0194823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0194823</ArticleId>
            <ArticleId IdType="pmc">PMC5877862</ArticleId>
            <ArticleId IdType="pubmed">29601605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odutola A, Ota MOC, Antonio M, Ogundare EO, Saidu Y, Foster-Nyarko E, Owiafe PK, Ceesay F, Worwui A, Idoko OT, et al. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: a phase 2, randomized, controlled, observer-blind study. Vaccine. 2017;35(19):2531–42. doi:10.1016/j.vaccine.2017.03.071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2017.03.071</ArticleId>
            <ArticleId IdType="pubmed">28389097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pomat WS, van den Biggelaar AHJ, Wana S, Francis JP, Solomon V, Greenhill AR, Ford R, Orami T, Passey M, Jacoby P, et al. Safety and immunogenicity of pneumococcal conjugate vaccines in a high-risk population: a randomized controlled trial of 10-valent and 13-valent pneumococcal conjugate vaccine in Papua New Guinean infants. Clin Infect Dis. 2019;68(9):1472–81. doi:10.1093/cid/ciy743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciy743</ArticleId>
            <ArticleId IdType="pmc">PMC6481999</ArticleId>
            <ArticleId IdType="pubmed">30184183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Oliveira LH, Shioda K, Valenzuela MT, Janusz CB, Rearte A, Sbarra AN, Warren JL, Toscano CM, Weinberger DM, Multinational Study for PCV Impact in Mortality Study Team. Declines in pneumonia mortality following the introduction of pneumococcal conjugate vaccines in Latin American and Caribbean countries. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciaa614</ArticleId>
            <ArticleId IdType="pmc">PMC8516507</ArticleId>
            <ArticleId IdType="pubmed">32448889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gisselsson-Solen M. Trends in otitis media incidence after conjugate pneumococcal vaccination: a national observational study. Pediatr Infect Dis J. 2017;36(11):1027–31. doi:10.1097/inf.0000000000001654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/inf.0000000000001654</ArticleId>
            <ArticleId IdType="pubmed">28657970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Edmondson-Jones M, Dibbern T, Hultberg M, Anell B, Medin E, Feng Y, Talarico C. The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions. Hum Vaccin Immunother. 2020;1–10. doi:10.1080/21645515.2020.1775455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2020.1775455</ArticleId>
            <ArticleId IdType="pmc">PMC7899701</ArticleId>
            <ArticleId IdType="pubmed">32574101</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
